BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, January 14, 2025
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 3, 2017
View Archived Issues
AstraZeneca reviews key product and pipeline highlights of second quarter 2017
Read More
Daiichi Sankyo reflects on accomplishments of first quarter of fiscal 2017
Read More
CerSci Therapeutics obtains grant to support development of CT-044
Read More
Sanofi updates key developments of second quarter 2017
Read More
LAIV H5N2 vaccine demonstrates safety and long-lasting memory immune responses in healthy subjects
Read More
P2-VP8-P[8] subunit rotavirus vaccine shows safety and immunogenicity in toddlers and infants
Read More
Velusetrag improves symptoms in patients with gastroparesis in phase IIb study
Read More
Reduced tachyphylaxis seen in vivo with novel D1 receptor agonists
Read More
MRC announces two new partnerships with industry to speed drug discovery
Read More
Qu Biologics reports positive results from phase II study of QBECO
Read More
Helsinn and MEI Pharma begin phase III testing of pracinostat
Read More
IL-36 receptor identified as therapeutic target for IBD
Read More
Dosing begins in phase I study of Bolder Biotechnology's BBT-015
Read More
U.S. researchers patent EAAT2 activators
Read More
Bristol-Myers Squibb presents ROCK2 inhibitors
Read More
Kymab provides update on phase I study of KY-1005
Read More
Boehringer Ingelheim discloses BTK and IL-6 production inhibitors
Read More
RSV inhibitors identified by Enanta Pharmaceuticals
Read More
BioMarin to open additional phase III studies based on phase I/II data of BMN-270
Read More
FDA's arthritis advisory committee does not recommend approval of sirukumab for the treatment of RA
Read More
X4 Pharmaceuticals and Yale to work on genetic model of WHIM syndrome
Read More
FDA grants approval to ibrutinib for adult patients with chronic GvHD
Read More
Aclaris Therapeutics submits IND to FDA for ATI-50002
Read More
Proteostasis Therapeutics gives update on cystic fibrosis projects
Read More
IGF2BP3 found to be a novel target in thyroid cancer
Read More
Molecular Templates' merger with Threshold Pharmaceuticals completed
Read More
Takeda Pharmaceutical enters partnership with Cardurion Pharmaceuticals
Read More
Positive phase IIa results for GBR-830 as treatment of patients with atopic dermatitis
Read More